CDH1 and central nervous system cancer: Moreover, in a series of low-grade gliomas, CDH1 promoter methylation status was found to be frequent (65% astrocytomas, 66% oligodendrogliomas, and 57% oligoastrocytomas) and hypermethylation status associated with shorter progression-free survival [146].